ZyVersa Therapeutics Other Current Liabilities

ZyVersa Therapeutics (ZVSA) currently reports a other current liabilities of $14B as of March 2026. That compares with $-7.2B in the prior-year period — up 289.5% year over year. Use the charts on this page to explore ZyVersa Therapeutics's other current liabilities history and peer comparisons.

ZyVersa Therapeutics's other current liabilities increased from $-7.2B to $14B — a 289.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ZyVersa Therapeutics reported $14B in other current liabilities as of March 2026. That compares with $-7.2B in the prior-year period — up 289.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $14B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ZyVersa Therapeutics, and consider following ZVSA for alerts when major investors trade the stock.